Balanced news tone
News Sentiment
MENS sentiment intelligence
Jyong Biotech Ltd. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
43 relevant articles
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
-0.5% over one week, +39.9% over four weeks, trend inactive, and below fair value.
Doctor shares the ‘most troubling trend’ in men’s health — and why biohacking is to blame
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
88/100 classification
One-week reaction
-0.5%
Price digesting
Trend fit
Trend inactive
39.9% over four weeks
Fair value
-88.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
12
Neutral
26
Negative
5
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
New York Post
Direct company coverage
Doctor shares the ‘most troubling trend’ in men’s health — and why biohacking is to blame
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 15:26
- Source
- New York Post
Investing.com
Direct company coverage
Jyong Biotech presents drug candidate at BIO 2026 convention
Jyong Biotech participated in the BIO International Convention, presenting its botanical drug candidate, Botreso (API-1), for benign prostatic hyperplasia. The company is preparing a New Drug Application and pursuing global licensing, actively discussing commercialization with ph
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 02 Jul 2026 13:15
- Source
- Investing.com
Pluang
Direct company coverage
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment.
Jyong Biotech showcased its botanical drug candidate Botreso® at BIO 2026, demonstrating its potential for treating benign prostatic hyperplasia (BPH) and lower urinary tract symptoms through successful Phase III trials. The company is preparing its New Drug Application and activ
- Tone
- Positive 86/100
- Event
- Market update
- Published
- 02 Jul 2026 12:15
- Source
- Pluang
Stock Titan
Direct company coverage
Jyong Biotech pitched its plant-based BPH drug to pharma partners at BIO 2026
Jyong Biotech (Nasdaq: MENS) showcased its botanical drug portfolio, including the Phase III candidate Botreso (API-1) for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), at the BIO 2026 International Convention. The company is actively pursuing global
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 02 Jul 2026 12:15
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
Jyong Biotech showcased its botanical drug portfolio, including its lead candidate Botreso®, at the BIO 2026 International Convention. The company is actively pursuing global licensing discussions for Botreso®, which targets benign prostatic hyperplasia (BPH) and lower urinary tr
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 02 Jul 2026 12:15
- Source
- GlobeNewswire
TradingView
Direct company coverage
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS
This article provides financial information for Jyong Biotech Ltd. (NASDAQ: MENS), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades recorded.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 01:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS
This page provides information about the Price to Sales Forward metric for Jyong Biotech Ltd. (NASDAQ: MENS). It confirms that the market is closed, with no trades, and the data is provided by ICE Data Services and FactSet.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 20:39
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS
This article provides financial information for Jyong Biotech Ltd. (NASDAQ:MENS), specifically focusing on its enterprise value to EBIT forward. It indicates available data on this metric, reflecting current financial health and forward-looking valuation.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 18:11
- Source
- TradingView
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Jyong Biotech Ltd (MENS), covering its support, resistance levels, and various technical indicators. It details individual indicator values like MACD, RSI, and moving averages (MA5, MA10, MA20, MA50, MA100, MA200), offering a summary
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 13:40
- Source
- TradingKey
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Jyong Biotech Ltd (MENS) dividend and stock split history, indicating that no dividends have been distributed in the past 5 years and no stock splits have occurred. It also presents basic stock information like its current trading price, marke
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 21:40
- Source
- TradingKey
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Jyong Biotech Ltd (MENS), listing major individual and institutional holders. Key shareholders include Perfect Minds Co Ltd, Laxton Investments Company Ltd, and Linkage Gladden Enterprise Ltd, alongside a breakdown by shareholder
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 16:10
- Source
- TradingKey
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Jyong Biotech Ltd (MENS), covering its stock performance and various risk metrics. It includes financial data such as market capitalization, daily returns, volatility, and liquidity, but several specific figures are listed as "—" or "0.
- Tone
- Negative 39/100
- Event
- Balance sheet
- Published
- 17 Jun 2026 15:42
- Source
- TradingKey
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Institutional Confidence
This article from TradingKey provides details on the institutional confidence in Jyong Biotech Ltd (MENS), listing key shareholders and their holdings. The stock closed at $1.590 with a minor dip and has a market cap of $121.64M. The institutional shareholding data shows several
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 18:40
- Source
- TradingKey
TradingKey
Direct company coverage
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Jyong Biotech Ltd (MENS), detailing its current stock price, market cap, and trading performance. It notes that key valuation metrics such as P/E, P/B, P/S, and P/CF have not been disclosed by the company. The article serves as a bri
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 16:40
- Source
- TradingKey
www.marketscreener.com
Direct company coverage
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.
Certain ordinary shares of Jyong Biotech Ltd. are under a lock-up agreement set to expire on June 16, 2026. This lock-up period, starting from June 16, 2025, affects directors, officers, and holders of more than 5% of outstanding shares for 365 days, while holders of less than 5%
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 02:10
- Source
- www.marketscreener.com
ChartMill
Direct company coverage
JYONG BIOTECH LTD (MENS) Stock Chart
The article provides a stock chart for JYONG BIOTECH LTD (MENS), listed on NASDAQ. As of June 9, 2026, at 01:23 PM, the stock price was 1.85 USD, down 0.15 (-7.5%). The page offers various tools and data for stock analysis.
- Tone
- Negative 32/100
- Event
- Market update
- Published
- 05 Jun 2026 17:39
- Source
- ChartMill
Finviz
Direct company coverage
MENS - Jyong Biotech Ltd Stock Price and Quote
This article provides detailed stock information for Jyong Biotech Ltd (MENS), including its last closing price, financial metrics, performance indicators, and recent news announcements. It covers key data such as market capitalization, P/E ratios, employee count, and details abo
- Tone
- Positive 64/100
- Event
- Market update
- Published
- 30 May 2026 14:39
- Source
- Finviz
Pluang
Direct company coverage
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia.
Jyong Biotech's CEO, Fu-Feng Kuo, detailed the company's strategy to secure FDA approval for Botreso®, a botanical drug for benign prostatic hyperplasia (BPH) affecting over 12 million men in the US. The company has completed pivotal studies, showing a strong safety profile, and
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 29 May 2026 13:39
- Source
- Pluang
GlobeNewswire
Direct company coverage
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview
Jyong Biotech's CEO, Ms. Fu-Feng Kuo, detailed the company's FDA pathway and global strategy in a PharmaBoardroom interview. The company is developing plant-derived therapeutics, notably Botreso® for benign prostatic hyperplasia (BPH), and emphasizes a strong focus on the U.S. ma
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 May 2026 12:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
12M Americans have BPH; one biotech is testing a plant-based option
Jyong Biotech is advancing Botreso, a plant-based drug targeting benign prostatic hyperplasia (BPH) with 12.2 million US patients, and a prostate cancer prevention asset, PCP. The company highlighted its FDA pathway, which includes additional US studies, aiming for a combined NDA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 11:59
- Source
- Stock Titan
Simply Wall Street
Direct company coverage
Jyong Biotech (Nasdaq:MENS) - Stock Analysis
Jyong Biotech (Nasdaq:MENS) is a science-driven biotechnology company developing plant-derived drugs for urinary system diseases. The company reported a delayed 20-F filing and provided updates on its botanical drugs, Botreso, PCP (MCS-8), and MCS-2, highlighting their clinical e
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 28 May 2026 12:39
- Source
- Simply Wall Street
Quiver Quantitative
Direct company coverage
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025
Jyong Biotech Ltd. announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2025, with the U.S. SEC on May 14, 2026. The Taiwan-based biotechnology company specializes in developing plant-derived therapeutics for urinary system diseases and o
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 12:44
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Inside Jyong Biotech's 2025 SEC annual report filing for investors
Jyong Biotech (Nasdaq: MENS) announced the filing of its Form 20-F annual report for the fiscal year ended December 31, 2025, with the SEC on May 14, 2026. The report is accessible on the company’s investor relations site and the SEC website, detailing key financial figures like
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 May 2026 12:39
- Source
- Stock Titan
GlobeNewswire
Direct company coverage
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Ltd. announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission on May 14, 2026. The report is accessible on the company's investor relations website and the SEC's website, with har
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2026 12:39
- Source
- GlobeNewswire
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
TipRanks
Direct company coverage
Jyong Biotech Delays Annual 20-F (Yearly Report)
Jyong Biotech Ltd. (MENS) has announced a delay in filing its annual Form 20-F for the fiscal year ending December 31, 2025, due to additional time needed to finalize audited financial statements. The company anticipates filing within 15 calendar days of the original due date and
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 29 Apr 2026 18:10
- Source
- TipRanks